

List of publications

A. ORIGINAL MANUSCRIPTS

1996

1. **Hartmann G**, Krug A, Eigler A, Moeller J, Murphy J, Albrecht R, Endres S. Specific suppression of human tumor necrosis factor- α synthesis by antisense oligodeoxynucleotides. *Antisense Nucleic Acid Drug Dev* 1996; 6: 291-99.
2. **Hartmann G**, Krug A, Waller-Fontaine K, Endres S. Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin. *Mol Med* 1996; 2: 429-438.

1997

3. **Hartmann G**, Krug A, Bidlingmaier M, Eigler A, Endres S. Antisense strategies for inhibition of TNF- α synthesis. *Nucleos Nucleot Nucl Acid* 1997; 16: 629-34.
4. Siegmund B, Eigler A, Sinha B, Moeller J, **Hartmann G**, Endres S. Supression of tumor necrosis factor-alpha production by interleukin-10 is enhanced by cAMP-elevating agents. *Eur J Pharmacol* 1997; 321:231-239

1998

5. **Hartmann G**, Krug A, Bidlingmaier M, Hacker U, Eigler A, Albrecht R, Strasburger CJ, Endres S. Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes. *J Pharmacol Exp Ther* 1998; 285: 920-28.
6. **Hartmann G**, Bidlingmaier M, Jahrsdörfer B, Krug A, Hacker U, Eigler A, Endres S. Oligonucleotide uptake in leukocytes is dependent on extracellular calcium: a hint for the involvement of adhesion molecules? *Nucleos Nucleot Nucl Acid* 1998; 17: 1767-73.
7. Siegmund B, Eigler A, **Hartmann G**, Hacker U, Endres S. Adrenaline enhances LPS-induced IL-10 synthesis: evidence for protein kinase A-mediated pathway. *Int J Immunopharmacol* 1998; 20:57-69
8. Eigler A, Waller-Fontaine K, Moeller J, **Hartmann G**, Hacker UT, Endres S. The hairy cell leukemia cell line Eskol spontaneously synthesizes tumor necrosis factor-alpha and nitric oxide. *Leuk Res* 1998;22:501-7.
9. Hacker UT, Bidlingmaier C, Gomolka M, Keller E, Eigler A, **Hartmann G**, Folwaczny C, Fricke H, Albert E, Loeschke K, Endres S. Inflammatory bowel disease: no association between allele combinations of the interleukin (IL) 1 beta and IL-1 receptor antagonist gene polymorphisms. *Eur J Clin Invest.* 1998;28:214-9.

10. Hacker UT, Jelinek T, Erhardt S, Eigler A, **Hartmann G**, Nothdurft HD, Endres S. In vivo synthesis of tumor necrosis factor- α in healthy humans after live yellow fever vaccination. *J Infect Dis* 1998;177:774-8.

11. Eigler A, Siegmund B, Emmerich U, Baumann KH, **Hartmann G**, Endres S. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. *J Leukoc Biol* 1998;63:101-7.

1999

12. **Hartmann G**, Krieg AM. CpG DNA and LPS induce distinct patterns of activation in human monocytes. *Gene Ther* 1999; 6:893.

13. **Hartmann G**, Weiner G, Krieg AM. CpG DNA as a signal for growth, activation and maturation of human dendritic cells *PNAS* 1999; 96:9305

2000

14. **Hartmann G.**, and Krieg A. M. Mechanism and function of a newly identified CpG DNA motif in human primary cells. *J Immunol* 2000;164:944

15. **Hartmann G.**, Weeratna R. D., Ballas Z. K., Payette P., Blackwell S., Suparto I., Rasmussen W. L., Waldschmidt M., Sajuthi D., Purcell R. H., Davis H. L., and Krieg A. M. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. *J Immunol* 2000; 164: 1617

16. **Hartmann G.**, Tschoep, M., Fischer, R., Bidlingmaier, C., Riepl, R., Tschoep, K., Hautmann, H., Endres, S. and Toepfer, M. High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein. *Cytokine* 2000;12:246-52.

17. **Hartmann G**, Bidlingmaier C, Siegmund B, Albrich S, Schulze J, Tschöp K, Eigler A, Lehr HA, Endres S. The specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. *J Pharmacol Exp Ther* 2000;292:22-30

18. Eigler A, Matschke V, **Hartmann G**, Erhardt S, Boyle D, Firestein GS, Endres S. Suppression of TNF- α production in human mononuclear cells by an adenosine kinase inhibitor. *J Leuk Biol* 2000; 68:97-103.

19. Brunner C, Seiderer J, Bidlingmaier M, Eigler A, Haimerl W, Lehr HA, Krieg A, **Hartmann G**, Endres S. Dendritic cell maturation by tumor factor- α or CpG oligodeoxynucleotide enhances T-cell-activating potential *in vitro* and protection against experimental murine colon carcinoma *in vivo*. *J Immunol* 2000; 165:6278-86

2001

20. Jahrsdörfer B°, **Hartmann G**° Racila E, Meinhardt G, Endres S, Krieg AM, Weiner GJ. CpG DNA increases immunogenicity and target-antigen expression of primary B cell non-Hodgkin lymphoma cells. (°contributed equally). *J Leuk Biol* 2001; 69:81-88

21. Siegmund B, Albrich S, Rieder F, Wolf K, Firestein GS, Boyle D, Lehr HA,

- Hartmann G**, Endres S, Eigler A. The adenosine kinase inhibitor GP515 improves experimental colitis in mice. *J Pharmacol Exp Ther* 2001; 296:99-105
22. Tschoep K°, **Hartmann G**°, Eigler A, Krug A, Erhardt S, Adams G, Endres S, Delius M. Shock waves: a novel method for intracytoplasmic delivery of antisense oligonucleotides. (°contributed equally). *J Mol Med* 2001; 79:306-13
23. Krug, A., Rothenfusser, S., Hornung, V., Jahrsdörfer, B., Ballas, Z., Endres, S., Krieg, A. M. and **Hartmann, G.**, Identification of CpG oligonucleotide sequences with high induction of IFN- α - β in plasmacytoid dendritic cells. *Eur J Immunol* 2001; 31:2154-63
24. Krug, A., Towarowski, A., Britsch, S., Rothenfusser, S., Hornung, V., Bals, R., Giese, T., Engelmann, H., Endres, S., Krieg, A. M., **Hartmann, G.**, Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40L to induce high amounts of IL-12. *Eur J Immunol* 2001, 31: 3026-37
25. Siegmund B, Fantuzzi G, Rieder F, Gamboni-Robertson F, Lehr HA, **Hartmann G**, Dinarello CA, Endres S, Eigler A. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. *Am J Physiol* 2001; 281:1264-73
26. Rothenfusser S, Hornung V, Krug A, Towarowski A, Krieg AM, Endres, S and **Hartmann G**. Distinct CpG oligonucleotide sequences activate human $\gamma\delta$ T cells via interferon-alpha/beta. *Eur J Immunol* 2001; 31:3525-3534
- 2002**
27. Zou W, Schwartz H, Endres S, **Hartmann G** and Bar-Shavit-Z. CpG oligonucleotides: novel regulators of osteoclast differentiation. *FASEB J* 2002; 16:274-82
28. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdoerfer B, Giese T, Endres S and **Hartmann G**. Quantitative expression of TLR1-10 mRNA in cellular subsets of human PBMC and sensitivity to CpG ODN. *J Immunol* 2002; 168:4531-37
29. Jahrsdorfer B, Jox R, Muhlenhoff L, Tschoep K, Krug A, Rothenfusser S, Meinhardt G, Emmerich B, Endres S, **Hartmann G**. Modulation of malignant B cell apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. *J Leuk Biol* 2002, 72:83-92
30. Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdörfer B, Krug A, Rothenfusser S, Endres S and **Hartmann G**. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. *J Immunol* 2002; 169:3892-9
31. Heckelsmiller K, Beck S, Rall K, Sipos B, Schlamp A, Tuma E, Rothenfusser S, Endres S and **Hartmann G**. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors which resist chemotherapy. *Eur J Immunol* 2002 32:3235-3245 (JIF 4.5)

32. Wollenberg A, Wagner M, Günther S, Towarowski A, Tuma E, Moderer M, Rothenfusser S, Endres S and **Hartmann G**. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. *J Invest Dermatol* 2002 119:1096-102

2003

33. Krug, A., S. Rothenfusser, S. Selinger, C. Bock, M. Kerkmann, J. Battiany, A. Sarris, T. Giese, D. Speiser, S. Endres, and **G. Hartmann**. 2003. CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells. *J Immunol*; 2003 170: 3468-77

34. Kerkmann, M., S. Rothenfusser, V. Hornung, A. Towarowski, M. Wagner, A. Sarris, T. Giese, S. Endres, and **G. Hartmann**. 2003. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. *J Immunol*; 2003 170:4465-74

35. **Hartmann, G.**, J. Battiany, H. Poeck, M. Wagner, M. Kerkmann, N. Lubenow, S. Rothenfusser, and S. Endres. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN- α induction in plasmacytoid dendritic cells. *Eur J Immunol*; 2003; 33: 1633-41

36. Hartmann, E., B. Wollenberg, S. Rothenfusser, M. Wagner, D. Wellisch, B. Mack, T. Giese, O. Gires, S. Endres, and **G. Hartmann**. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. *Cancer Research* 2003; 63:6478-87

2004

37. Rothenfusser S., Hornung V., Ayyoub M., Britsch S., Towarowski A., Krug A., Sarris A., Lubenow N., Speiser D., Endres S. and **Hartmann G**. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8⁺ T cell responses in vitro. *Blood* 2004; 103:2162-9

38. Poeck H., Wagner M., Battiany J., Rothenfusser S., Wellisch D., Hornung V., Giese T., Endres S., and **Hartmann G**. Plasmacytoid dendritic cells, antigen and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T cell help. *Blood* 2004; 103:3058-64

39. Costa LT, Kerkmann M, **Hartmann G**, Endres S, Bisch PM, Heckl WM, Thalhammer S. Structural studies of oligonucleotides containing G-quadruplex motifs using AFM. *Biochem Biophys Res Commun* 2004; 313:1065-72

40. Wagner M., Poeck H., Jahrsdörfer B., Rothenfusser S., Prell D., Bohle B., Tuma E. Giese T., Ellwart JW., Endres S., and **Hartmann G**. IL-12p70 dependent Th1 induction by human B cells requires combined activation with CD40L and CpG DNA. *J Immunol* 2004; 172:954-63

41. Schnurr M., Toy T., Shin A., **Hartmann G.**, Rothenfusser S., Ian D. Davis ID., Cebon J., and Maraskovsky E.. Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. *Blood* 2004; 103:1391-7
42. Krepler C., V. Wacheck, S. Strommer, **G. Hartmann**, P. Polterauer, K. Wolff, H. Pehamberger, B. Jansen. CpG oligonucleotides elicit anti-tumor responses in a human melanoma NOD/SCID xenotransplantation model. *J Invest Dermatol* 2004; 122:387-91
43. Freyschmidt E.J., Alonso A., **Hartmann G.**, L. Gissmann. Activation of dendritic cells and induction of T cell responses by human papillomavirus type 16 (HPV 16) L1/E7 chimeric viruslike particles are enhanced by CpG ODN or sorbitol. *Antiviral Therapy* 2004; 9:479-89
44. Hornung V. Schlender J, Guenther-Biller M., Rothenfusser S, Endres S., Conzelmann KK, and **Hartmann G** Replication dependent potent IFN- α induction in human plasmacytoid dendritic cells by a single-stranded RNA virus. *J Immunol* 2004, 173:5935-43.

2005

45. Kerkmann M., Costa L.T., Richter C., Rothenfusser S., Battiany J., Hornung V., Johnson J., Englert S., Ketterer T., Heckl W., Thalhammer S., Endres S., and **Hartmann G.** Spontaneous formation of nucleic acid-based nanoparticles is responsible for high IFN- α induction by CpG-A in plasmacytoid dendritic cells. *J Biol Chem* 2005, 280:8086-93
46. Jahrsdorfer B., Mühlenhoff L., Blackwell S.E., Wagner M., Poeck H., Hartmann E., Jox R., Giese T., Emmerich B., Endres S., Weiner G.J. and **Hartmann G.** B cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. *Clinical Cancer Research* 2005;11:1490-9
47. Hornung V, Guenther-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A., Endres S and **Hartmann G.** Sequence-specific potent induction of IFN- α by short interfering RNA in plasmacytoid dendritic cells through TLR7. *Nat Med* 2005, 11:263-70.
48. Bekeredjian-Ding IB, Wagner M, Hornung V, Giese T, Schnurr M, Endres S and **Hartmann G.** Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. *J Immunol* 2005; 174:4043-50.
49. **Hartmann G.**, Sarris A., Viveros P.R., Stahl-Hennig C., Hornung V., Tenner-Racz K., Racz P., Steinman R.M. and Ignatius R. CpG oligonucleotides enhance humoral immune responses without supporting CD4 T cell responses in rhesus macaques in vivo. *Vaccine* in press.
50. Schlender J., Hornung V., Finke S., Marozin S., Brzózka K., Endres S., **Hartmann G.**, and Conzelmann K.K. Viral Inhibition of TLR7- and TLR9-mediated IFN production in PDC. *J Virol* 2005; 79: 5507-5515.
51. Marschner A, Rothenfusser S, Hornung V, Prell D, Krug A, Kerkmann M, Wellisch D, Poeck H, Greinacher A, Giese T, Endres S and **Hartmann G.** CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells. *Eur J Immunol* 2005; 35(8):2347-57.

52. Renner ED, Pawlita I, Hoffmann F, Hornung V, Hartl D, Albert M, Jansson A, Endres S, **Hartmann G**, Belohradsky BH, Rothenfusser S. No indication for a defect in toll-like receptor signaling in patients with hyper-IgE syndrome. *J Clin Immunol*. 2005 Jul;25(4):321-8.

2006

53. Bourquin C, Schreiber S, Beck S, **Hartmann G**, Endres S. Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer. *Int J Cancer*. 2006;118:2790-5.

54. Bekeredjian-Ding I, Roth SI, Gilles S, Giese T, Ablasser A, Hornung V, Endres S and **Hartmann G**. T cell independent, TLR-induced IL-12p70 production in primary human monocytes. *J Immunol* 2006; 176:7438-46

55. Hornung V, Ellegast J, Kim S, Brzoka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, Endres S, and **Hartmann G**. 5'-Triphosphate RNA Is the Ligand for RIG-I. *Science* 2006; Nov 10; 314:994-7

56. Bourquin C, Schmidt L, Hornung V, Wurzenberger C, Anz D, Sandholzer N, Schreiber S, Voelkl A, **Hartmann G**, and Endres S. Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T cell and IgG2a response. *Blood* 2006

57. Kerkmann M, Lochmann D, Weyermann J, Marschner A, Poeck H, Wagner M, Battiany J, Zimmer A, Endres S, **Hartmann G**. Immunostimulatory properties of CpG-oligonucleotides are enhanced by the use of protamine nanoparticles. *Oligonucleotides*. 2006 16:313-22.

2007

57. Bourquin C, Schmidt L, Hornung V, Wurzenberger C, Anz D, Sandholzer N, Schreiber S, Voelkl A, **Hartmann G**, and Endres S. Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T cell and IgG2a response. *Blood* 2007;109:2953-60

58. Bekeredjian-Ding I, Inamura S, Giese T, Moll H, Endres S, Sing A, Zähringer U, **Hartmann G**. *Staphylococcus aureus* triggers T cell-independent B cell proliferation through the engagement of the B cell receptor and Toll-like receptor 2. *J Immunol*. 2007;178:2803-12

59. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M, Lin C, Socci ND, Hermida L, Fulci V, Chiaretti S, Foa R, Schliwka J, Fuchs U, Novosel A, Muller RU, Schermer B, Bissels U, Inman J, Phan Q, Chien M, Weir DB, Choksi R, De Vita G, Frezzetti D, Trompeter HI, Hornung V, Teng G, **Hartmann G**, Palkovits M, Di Lauro R, Wernet P, Macino G, Rogler CE, Nagle JW, Ju J, Papavasiliou FN, Benzing T, Lichter P, Tam W, Brownstein MJ, Bosio A, Borkhardt A, Russo JJ, Sander C, Zavolan M, Tuschl T. A mammalian microRNA expression atlas based on small RNA library sequencing. *Cell*. 2007 Jun 29;129(7):1401-14.

60. Zwioerek K, Bourquin C, Battiany J, Winter G, Endres S, **Hartmann G**, Coester C. Delivery by Cationic Gelatin Nanoparticles Strongly Increases the Immunostimulatory Effects of CpG Oligonucleotides. *Pharm Res*. 2007 Oct 3

2008

61. Allam, R., Pawar, R.D., Kulkarni, O.P., Hornung, V., **Hartmann, G.**, Segerer, S., Akira, S., Endres, S., Anders, H.J. (2008) Viral 5'-triphosphate RNA and non-CpG DNA aggravate autoimmunity and lupus nephritis via distinct TLR-independent immune responses. *Eur J Immunol* 38, 3487-98.
62. Michallet, M.C., Meylan, E., Ermolaeva, M.A., Vazquez, J., Rebsamen, M., Curran, J., Poeck, H., Bscheider, M., **Hartmann, G.**, Konig, M., Kalinke, U., Pasparakis, M., Tschopp, J. (2008) TRADD protein is an essential component of the RIG-like helicase antiviral pathway. *Immunity* 28, 651-61.
63. Poeck, H., Besch, R., Maihoefer, C., Renn, M., Tormo, D., Morskaya, S.S., Kirschnek, S., Gaffal, E., Landsberg, J., Hellmuth, J., Schmidt, A., Anz, D., Bscheider, M., Schwerd, T., Berking, C., Bourquin, C., Kalinke, U., Kremmer, E., Kato, H., Akira, S., Meyers, R., Hacker, G., Neuenhahn, M., Busch, D., Ruland, J., Rothenfusser, S., Prinz, M., Hornung, V., Endres, S., Tuting, T., **Hartmann, G.** (2008) 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. *Nat Med* 14, 1256-63.
64. Zwioerek, K., Bourquin, C., Battiany, J., Winter, G., Endres, S., **Hartmann, G.**, Coester, C. (2008) Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. *Pharm Res* 25, 551-62.

2009

65. Ablasser, A., Bauernfeind, F., **Hartmann, G.**, Latz, E., Fitzgerald, K.A., Hornung, V. (2009) RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. *Nat Immunol* 10, 1065-72.
66. Ablasser, A., Poeck, H., Anz, D., Berger, M., Schlee, M., Kim, S., Bourquin, C., Goutagny, N., Jiang, Z., Fitzgerald, K.A., Rothenfusser, S., Endres, S., **Hartmann, G.**, Hornung, V. (2009) Selection of molecular structure and delivery of RNA oligonucleotides to activate TLR7 versus TLR8 and to induce high amounts of IL-12p70 in primary human monocytes. *J Immunol* 182, 6824-33.
67. Bekeredjian-Ding, I., Schafer, M., Hartmann, E., Pries, R., Parcina, M., Schneider, P., Giese, T., Endres, S., Wollenberg, B., **Hartmann, G.** (2009) Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha. *Immunology* 128, 439-50.
68. Berger, M., Ablasser, A., Kim, S., Bekeredjian-Ding, I., Giese, T., Endres, S., Hornung, V., **Hartmann, G.** (2009) TLR8-driven IL-12-dependent reciprocal and synergistic activation of NK cells and monocytes by immunostimulatory RNA. *J Immunother* 32, 262-71.
69. Besch, R., Poeck, H., Hohenauer, T., Senft, D., Hacker, G., Berking, C., Hornung, V.,

- Endres, S., Ruzicka, T., Rothenfusser, S., **Hartmann, G.** (2009) Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. *J Clin Invest* 119, 2399-411.
70. Bourquin, C., Schmidt, L., Lanz, A.L., Storch, B., Wurzenberger, C., Anz, D., Sandholzer, N., Mocikat, R., Berger, M., Poeck, H., **Hartmann, G.**, Hornung, V., Endres, S. (2009) Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through the TLR7. *J Immunol* 183, 6078-86.
71. Coch, C., Busch, N., Wimmenauer, V., Hartmann, E., Janke, M., Abdel-Mottaleb, M.M., Lamprecht, A., Ludwig, J., Barchet, W., Schlee, M., **Hartmann, G.** (2009) Higher activation of TLR9 in plasmacytoid dendritic cells by microbial DNA compared with self-DNA based on CpG-specific recognition of phosphodiester DNA. *J Leukoc Biol* 86, 663-70.
72. Garcia, M., Dogusan, Z., Moore, F., Sato, S., **Hartmann, G.**, Eizirik, D.L., Rasschaert, J. (2009) Regulation and function of the cytosolic viral RNA sensor RIG-I in pancreatic beta cells. *Biochim Biophys Acta* 1793, 1768-75.
73. Gross, O., Poeck, H., Bscheider, M., Dostert, C., Hanneschlager, N., Endres, S., **Hartmann, G.**, Tardivel, A., Schweighoffer, E., Tybulewicz, V., Mocsai, A., Tschopp, J., Ruland, J. (2009) Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. *Nature* 459, 433-6.
74. Janke, M., Poth, J., Wimmenauer, V., Giese, T., Coch, C., Barchet, W., Schlee, M., **Hartmann, G.** (2009) Selective and direct activation of human neutrophils but not eosinophils by Toll-like receptor 8. *J Allergy Clin Immunol* 123, 1026-33.
75. Kern, M., Popov, A., Scholz, K., Schumak, B., Djandji, D., Limmer, A., Eggle, D., Sacher, T., Zawatzky, R., Holtappels, R., Reddehase, M.J., **Hartmann, G.**, Debey-Pascher, S., Diehl, L., Kalinke, U., Koszinowski, U., Schultze, J., Knolle, P.A. (2009) Virally Infected Mouse Liver Endothelial Cells Trigger CD8(+) T-Cell Immunity. *Gastroenterology*.
76. Kohlmeyer, J., Cron, M., Landsberg, J., Bald, T., Renn, M., Mikus, S., Bondong, S., Wikasari, D., Gaffal, E., **Hartmann, G.**, Tuting, T. (2009) Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. *Cancer Res* 69, 6265-74.
78. Schlee, M., Roth, A., Hornung, V., Hagmann, C.A., Wimmenauer, V., Barchet, W., Coch, C., Janke, M., Mihailovic, A., Wardle, G., Juraneck, S., Kato, H., Kawai, T., Poeck, H., Fitzgerald, K.A., Takeuchi, O., Akira, S., Tuschl, T., Latz, E., Ludwig, J., **Hartmann, G.** (2009) Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. *Immunity* 31, 25-34.

2010

79. Yu CF, Peng WM, Oldenburg J, Hoch J, Bieber T, Limmer A, **Hartmann G**, Barchet W, Eis-Hübinger AM, Novak N. Human plasmacytoid dendritic cells support Th17 cell effector function in response to TLR7 ligation. *J Immunol*. 2010 Feb 1;184:1159-67

80. Anz D, Koelzer VH, Moder S, Thaler R, Schwerd T, Lahl K, Sparwasser T, Besch R, Poeck H, Hornung V, **Hartmann G**, Rothenfusser S, Bourquin C, Endres S. Immunostimulatory RNA blocks suppression by regulatory T cells. *J Immunol*. 2010; 184:939-46.
81. Poeck H, Bscheider M, Gross O, Finger K, Roth S, Rebsamen M, Hanneschläger N, Schlee M, Rothenfusser S, Barchet W, Kato H, Akira S, Inoue S, Endres S, Peschel C, **Hartmann G**[°], Hornung V[°], Ruland J[°]. Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. *Nat Immunol*. 2010;11:63-9. [°]equally contributed
82. Pölcher M, Eckhardt M, Coch C, Wolfgarten M, Kübler K, **Hartmann G**, Kuhn W, Rudlowski C. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. *Cancer Chemother Pharmacol*. 2010 May;66:203-7
83. Nakai N, Kishida T, **Hartmann G**, Katoh N, Imanishi J, Kishimoto S, Mazda O. Mitf silencing cooperates with IL-12 gene transfer to inhibit melanoma in mice. *Int Immunopharmacol*. 2010 Apr;10:540-5
84. Wang Y, Ludwig J, Schuberth C, Goldeck M, Schlee M, Li H, Juranek S, Sheng G, Micura R, Tuschl T[°], **Hartmann G**[°], Patel DJ[°]. 2010. Structural and functional insights into 5'-ppp RNA pattern recognition by the innate immune receptor RIG-I. *Nat Struct Mol Biol* 2010 Jul;17:781-7. [°]equally contributed
85. Kim S, Bauernfeind F, Ablasser A, **Hartmann G**, Fitzgerald KA, Latz E, Hornung V. *Listeria monocytogenes* is sensed by the NLRP3 and AIM2 inflammasome. *Eur J Immunol*. 2010 Jun;40:1545-51
86. Kübler K, Gehrke N, Riemann S, Böhnert V, Zillinger T, Hartmann E, Pölcher M, Rudlowski C, Kuhn W, **Hartmann G**, Barchet W. Targeted activation of RNA helicase retinoic acid-inducible gene-I induces proimmunogenic apoptosis of human ovarian cancer cells. *Cancer Res*. 2010;70:5293-304.
87. Poth JM, Coch C, Busch N, Boehm O, Schlee M, Janke M, Zillinger T, Schildgen O, Barchet W, **Hartmann G**. Monocyte-mediated inhibition of TLR9-dependent IFN- α induction in plasmacytoid dendritic cells questions bacterial DNA as the active ingredient of bacterial lysates. *J Immunol*. 2010 Dec 15;185:7367-73
- 2011
88. Koerner P, Traeger T, Mehmcke H, Cziupka K, Kessler W, Busemann A, Diedrich S, **Hartmann G**, Heidecke CD, Maier S. Stimulation of TLR7 prior to polymicrobial sepsis improves the immune control of the inflammatory response in adult mice. *Inflamm Res*. 2011 Mar;60:271-9
89. Herberhold S, Coch C, Zillinger T, Hommertgen B, Busch N, Schuberth C, Hartmann E, Wimmenauer V, Hagmann CA, Lüdenbach B, Schlee M, Bootz F, **Hartmann G**, Barchet W. Delivery with polycations extends the immunostimulant Ribomunyl into a potent antiviral Toll-

like receptor 7/8 agonist. *Antivir Ther.* 2011;16:751-8.

90. Debald M, Franken S, Heukamp LC, Linke A, Wolfgarten M, Walgenbach KJ, Braun M, Rudlowski C, Gieselmann V, Kuhn W, **Hartmann G**, Walgenbach-Brünagel G. Identification of specific nuclear structural protein alterations in human breast cancer. *J Cell Biochem.* 2011 Nov;112:3176-84

91. Kübler K, tho Pesch C, Gehrke N, Riemann S, Dassler J, Coch C, Landsberg J, Wimmenauer V, Pölcher M, Rudlowski C, Tüting T, Kuhn W, **Hartmann G**, Barchet W. Immunogenic cell death of human ovarian cancer cells induced by cytosolic poly(I:C) leads to myeloid cell maturation and activates NK cells. *Eur J Immunol.* 2011; 41:3028-39

92. Ebert G, Poeck H, Lucifora J, Baschuk N, Esser K, Esposito I, **Hartmann G**, Protzer U. 5' Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice. *Gastroenterology.* 2011;141:696-706

93. Sayyed SG, Ryu M, Kulkarni OP, Schmid H, Lichtnekert J, Grüner S, Green L, Mattei P, **Hartmann G**, Anders HJ. An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. *Kidney Int.* 2011 Jul;80:68-78

94. Zimmer S, Steinmetz M, Asdonk T, Motz I, Coch C, Hartmann E, Barchet W, Wassmann S, **Hartmann G**, Nickenig G. Activation of endothelial toll-like receptor 3 impairs endothelial function. *Circ Res.* 2011 May 27;108:1358-66

95. Dann A, Poeck H, Croxford A, Pfeifer D, Maihoefer C, Endres S, Kalinke U, Knust M, Knobloch KP, Akira S, Waisman A, **Hartmann G**, Prinz M. Systemic activation of RIG-I-like helicases limits Th1/Th17-mediated autoimmunity in the CNS. *Nature Neuroscience* 2011;15:98-106.

2012

96. Asdonk T, Motz I, Werner N, Coch C, Barchet W, **Hartmann G**, Nickenig G, Zimmer S. Endothelial RIG-I activation impairs endothelial function. *Biochem Biophys Res Commun.* 2012 Mar 30;420:66-71.

97. Marinova M, Lütjohann D, Breuer O, Kölsch H, Westhofen P, Watzka M, Mengel M, Stoffel-Wagner B, **Hartmann G**, Coch C, Oldenburg J. VKORC1-dependent pharmacokinetics of intravenous and oral phylloquinone (vitamin K1) mixed micelles formulation. *Eur J Clin Pharmacol.* 2012 Aug 5

98. Riepl RL, Fischer R, Hautmann H, **Hartmann G**, Müller TD, Tschöp M, Toepfer M, Otto B. Influence of acute exposure to high altitude on Basal and postprandial plasma levels of gastroenteropancreatic peptides. *PLoS One.* 2012;7(9):e44445. Epub 2012 Sep 6.

B REVIEWS

1. Eigler A, Sinha B, **Hartmann G**, Endres S. Taming TNF: strategies to restrain this proinflammatory cytokine. *Immunol Today* 1997; 18: 487-92
2. Toepfer M, **Hartmann G**, Tschöp M, Fischer R, Hautmann H, Riepl RL, Sepp F, Sattler D, Müller-Felber W, Huber RM. Prophylaxe und Therapie der Höhenkrankheit. *Münch Med Wschr* 1997; 139: 257-260.
3. **Hartmann G**, Bidlingmaier M, Eigler A, Hacker U, Endres S. Cytokines and therapeutic oligonucleotides. *Cytokines Cell Mol Ther* 1997; 3: 247-56
4. **Hartmann G**, Bidlingmaier M, Tschöp K, Eigler A, Hacker UT, Endres S. Antisense-Oligonukleotide: Nukleinsäuren zur gezielten Synthesehemmung krankheitsfördernder Proteine (Antisense-oligonucleotides: nucleic acids to knock down pathogenic target proteins). *Deutsches Ärzteblatt* 1998; Heft 24 (23):C-1115-1119
5. Krieg AM, Yi AK, **Hartmann G**. Mechanisms and therapeutic applications of immune stimulatory CpG DNA. *Pharmacol Ther.* 1999 84:113-20
6. Endres S, Siegmund B, **Hartmann G**, Eigler A. Pharmakologische Suppression der Synthese von Tumor-Nekrose-Faktor. *Arzneimittel Forschung Drug Research* 2000; 50:11-13.
7. Krieg AM, **Hartmann G**, Yi AK. Mechanism of action of CpG DNA. *Curr Topics Microbiol Immunol* 2000, 247:1-21
8. Rothenfuß S, Jahrsdörfer B, Krug A, Endres S and **Hartmann G**. CpG-Oligonukleotide: Therapie mit bakterieller DNA (CpG-oligonucleotides: therapy with bacterial DNA). *Deutsches Ärzteblatt* 2001, 98:981-985
9. Tamm I, Dörken B, **Hartmann G**. Antisense therapy in oncology: new hope for an old idea? *The Lancet* 2001; 358:489-97
10. Krug A, **Hartmann G**. Gezielte Modulation des Immunsystems mit CpG-Oligonukleotiden. *Deutsche Medizinische Wochenschrift* 2001; 1002-1004
11. Rothenfusser S, Krug A, **Hartmann G**. The plasmacytoid dendritic cell: the key to CpG. *Human Immunology* 2002; (Sonderausgabe „The plasmacytoid dendritic cell“ Edited by YJ Liu) 2002; 1111-1119
12. Rothenfusser, S., Tuma, E., M. Wagner, Endres, S., **Hartmann, G**. Recent advances in immunostimulatory CpG oligonucleotides. *Curr Opin Mol Ther* 2003; 5:98-106
13. **Hartmann G**, Endres S. Therapeutische Oligonukleotide, *Deutsches Ärzteblatt* 2003, 100 (47):3102
14. **Hartmann G**. Technology evaluation: BAY-50-4798, *Curr Opin Mol Ther* 2004 6:221-7
15. **Hartmann G**. TIDES 2006--IBC conference. Oligonucleotide and peptide technology and product development, IDrugs. 2006 Jul;9(7):460-3.

16. Schlee M, Hornung V, **Hartmann G**. siRNA and isRNA: two edges of one sword, *Mol Ther* 2006;14:463-70
17. Schlee, M., Barchet, W., Hornung, V., **Hartmann, G.** (2007) Beyond double-stranded RNA-type I IFN induction by 3pRNA and other viral nucleic acids. *Curr Top Microbiol Immunol* 316, 207-30.
18. Barchet, W., Wimmenauer, V., Schlee, M., **Hartmann, G.** (2008) Accessing the therapeutic potential of immunostimulatory nucleic acids. *Curr Opin Immunol* 20, 389-95.
19. Hornung, V., Barchet, W., Schlee, M., **Hartmann, G.** (2008) RNA recognition via TLR7 and TLR8. *Handb Exp Pharmacol*, 71-86.
20. **Hartmann, G.** (2009) Gene silencing below the immune radar. *J Clin Invest* 119, 438-42.
21. Schlee, M., Hartmann, E., Coch, C., Wimmenauer, V., Janke, M., Barchet, W., **Hartmann, G.** (2009) Approaching the RNA ligand for RIG-I? *Immunol Rev* 227, 66-74.
22. Nakai N, **Hartmann G**, Kishimoto S, Katoh N. Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters. *Pigment Cell Melanoma Res.* 2010
23. Schlee M, **Hartmann G**. The chase for the RIG-I ligand--recent advances. *Mol Ther.* 2010 Jul;18:1254-62.
24. van den Boorn JG, Schlee M, Coch C, **Hartmann G**. SiRNA delivery with exosome nanoparticles. *Nat Biotechnol.* 2011 Apr;29:325-6
25. Finger RP, Coch C, Coenen M, Mengel M, **Hartmann G**, Holz FG. [Basic principles, planning and implementation of non-commercial clinical trials]. *Ophthalmologe.* 2011 Jan;108:25-32.
26. van den Boorn JG, Barchet W, **Hartmann G**. Nucleic acid adjuvants: toward an educated vaccine. *Adv Immunol.* 2012;114:1-32.
27. Gilboa-Geffen A, **Hartmann G**, Soreq H. Stressing hematopoiesis and immunity: an acetylcholinesterase window into nervous and immune system interactions. *Front Mol Neurosci.* 2012;5:30.
28. van den Boorn JG, Daßler J, Coch C, Schlee M, **Hartmann G**. Exosomes as nucleic acid nanocarriers. *Adv Drug Deliv Rev.* 2012 Jun 28.

C LETTERS AND OTHER PUBLICATIONS

1. Hameister H., Klett C, **Hartmann G** and Ebensperger C. Comparative gene mapping: human chromosome 12 and mouse chromosome 15. 1994 in: *Chromosome 12 aberrations in human solid tumors*; ed. Bullerdiek and Bartnitzke (Springer, New York), Edtn, p. 73-78.

2. **Hartmann G.** and Endres S. N-3 polyunsaturated fatty acids and human cytokine synthesis. 1997 in: Handbook of essential fatty acid biology: biochemistry, physiology and behavioral neurobiology; ed. Yehuda and Mostofsky (Humana Press, Boston), p. 103-110.
3. **Hartmann G**, Endres S. (eds.) Manual of Antisense Technology. Stein CA (ser. ed.) Book series: Developments in Antisense Research. Kluwer Academic Publishers, Boston, 1999
4. **Hartmann G**, Bidlingmaier M, Jahrsdörfer B, Endres S. Oligonucleotides: extrapolating from *in vitro* to *in vivo*? *Nat Med* (letter) 1997; 3: 702.
5. Folwaczny C, Fricke H, Endres S, **Hartmann G**, Jochum M, Loeschke K. Anti-inflammatory properties of unfractionated heparin in patients with highly active ulcerative colitis: a pilot study. *Am J Gastroenterol* (letter) 1997;92:911-2
6. Tschöp M, Strasburger CJ, **Hartmann G**, Biollaz J, Bärtsch P. Elevated leptin levels at high altitude are associated with loss of appetite. *Lancet* (letter) 1998; 352: 1119-20.
7. Toepfer M, Lang SM, **Hartmann G**, Sitter T, Schiffel H. Plasma adrenomedullin levels, body fluid status, and end-stage renal failure. *Nephron* (letter) 1998; 80:232-3.
8. Toepfer M, **Hartmann G**, Schlosshauer M, Hautmann H, Tschop M, Fischer R, Huber RM. Adrenomedullin: a player at high altitude? *Chest* (letter) 1998;113:1428.
9. Hayashi, M., Kuwahara, M., Ogata, M., Miyao-Kurosaki, N., Abel, T., Ueki, R., Yano, M., Fujii, M., **Hartmann, G.**, Takaku, H. Evaluating the immune responses stimulated by CpG oligodeoxynucleotides. *Nucleic Acids Res Suppl.* 2003;(3):323-43
10. **Hartmann, G.** CpG: unraveling the key to B cell function. *Blood* (comment) 2003, 101:1
11. **Hartmann, G.**
Signaling in plasmacytoid dendritic cells. *J Immunol* (comment) 2003, 170
12. **Hartmann G.** A message from the Oligonucleotide Therapeutics Society. *Nucleic Acid Ther.* 2012 Feb;22:1-2
13. Ozawa A, Nomiyama T, Nakai N, **Hartmann G**, Takenaka H, Kishimoto S, Katoh N. Immunohistological analysis of in-transit metastasis in a patient with advanced melanoma treated with combination therapy of cytosine guanine dinucleotide oligodeoxynucleotide, dacarbazine and beta-interferon: A case report. *J Dermatol.* 2012 Mar 6.